Subscribe To
MSSTF / Mindset Pharma CEO spotlights firm's intranasal formulation technology, robust IP portfolio and partnerships
Content Topics
Mindset
Pharma
Spotlights
Firm
Intranasal
Formulation
Firm s
Technology
Robust
Portfolio
Partnerships
Stock
MSSTF
MSSTF News
By Proactive Investors
August 31, 2023
Mindset Pharma to be acquired by Otsuka Pharmaceutical in all-cash deal
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) announced that it has agreed to be acquired by Otsuka Pharmaceutical Co, Ltd, through its wholly-owned Ots more_horizontal
By Proactive Investors
June 22, 2023
Mindset Pharma's Phase 2 psilocin prodrug study gets green light from UK regulators
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) has received approval from the UK Medicines and Healthcare products Regulatory Authority and the Research E more_horizontal
By Proactive Investors
April 26, 2023
Mindset Pharma files two international patent applications under the Patent Cooperation Treaty
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) said it has filed two international patent applications under the Patent Cooperation Treaty (PCT) to prote more_horizontal
By Proactive Investors
March 28, 2023
Mindset Pharma CEO discusses expansion of drug discovery efforts into novel non-hallucinogenic therapeutics
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF). is expanding its drug discovery efforts into novel non-hallucinogenic therapeutics in light of the success more_horizontal
By Proactive Investors
March 6, 2023
Mindset Pharma and PharmAla complete first sale of pharmaceutical-grade psilocybin into growing Australian market via sales partnership
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) said PharmAla Biotech (CSE:MDMA) Holdings Inc has completed the first sale of a quantity of Mindset's pharm more_horizontal
By Proactive Investors
February 2, 2023
Mindset Pharma receives another allowance for US patent application expanding composition of matter for Family 1 psilocybin analogs
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) told investors that the US Patent and Trademark Office has granted allowance for another of its Family 1 p more_horizontal
By Proactive Investors
January 20, 2023
Mindset Pharma receives allowance for US patent application covering lead psychedelic therapeutic candidate
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) told investors that the US Patent and Trademark Office (USPTO) has granted allowance for its patent applica more_horizontal
By GlobeNewsWire
December 6, 2022
Mindset Pharma to Participate in Upcoming Conferences in December 2022
TORONTO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug more_horizontal